Business Description
Ind-Swift Laboratories Ltd
ISIN : INE915B01019
Share Class Description:
NSE:INDSWFTLAB: Shs DematerialisedTotal Employee Number:
1,246Compare
Compare
Traded in other countries / regions
532305.India IPO Date
1997-07-02Description
Ind-Swift Laboratories Ltd is involved in manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company serves various therapeutic segments, including Cardiovascular health, Antihistamines, Antidiabetics, Antipsychotics, Parkinson's disease, Antineoplastics, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitors. It operates solely in the pharmaceutical products sector. Geographically, the company supplies both domestic and international markets, with the majority of its revenue coming from outside India.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 23.02 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.31 | |||||
Interest Coverage | 9.04 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 5.22 | |||||
Beneish M-Score | -1.93 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -28.4 | |||||
3-Year EBITDA Growth Rate | -37.6 | |||||
3-Year Book Growth Rate | 11.4 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 87.17 | |||||
9-Day RSI | 85.77 | |||||
14-Day RSI | 82.78 | |||||
3-1 Month Momentum % | 13.15 | |||||
6-1 Month Momentum % | 71.61 | |||||
12-1 Month Momentum % | 37.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.8 | |||||
Quick Ratio | 3.22 | |||||
Cash Ratio | 1.83 | |||||
Days Inventory | 215.41 | |||||
Days Sales Outstanding | 138.39 | |||||
Days Payable | 217.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.7 | |||||
Shareholder Yield % | -8.37 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 55.76 | |||||
Operating Margin % | 0.48 | |||||
Net Margin % | 6.9 | |||||
EBITDA Margin % | 13.9 | |||||
FCF Margin % | -33.3 | |||||
OCF Margin % | -14.76 | |||||
ROE % | 2.53 | |||||
ROA % | 2.1 | |||||
ROIC % | 0.2 | |||||
3-Year ROIIC % | 17.15 | |||||
ROC (Joel Greenblatt) % | 8.49 | |||||
ROCE % | 3.17 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 55.6 | |||||
PE Ratio without NRI | 45.59 | |||||
Shiller PE Ratio | 32.74 | |||||
PS Ratio | 3.82 | |||||
PB Ratio | 1.34 | |||||
Price-to-Tangible-Book | 1.37 | |||||
EV-to-EBIT | 33.67 | |||||
EV-to-EBITDA | 21.43 | |||||
EV-to-Revenue | 2.98 | |||||
EV-to-FCF | -8.95 | |||||
Price-to-GF-Value | 5.79 | |||||
Price-to-Projected-FCF | 1.56 | |||||
Price-to-Graham-Number | 1.48 | |||||
| Price-to-Net-Current-Asset-Value | 2.7 | |||||
| Price-to-Net-Cash | 10.18 | |||||
Earnings Yield (Greenblatt) % | 2.97 | |||||
FCF Yield % | -8.47 | |||||
Forward Rate of Return (Yacktman) % | -13.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ind-Swift Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 4,732.844 | ||
| EPS (TTM) (₹) | 3.85 | ||
| Beta | 1.149 | ||
| 3-Year Sharpe Ratio | 0.6 | ||
| 3-Year Sortino Ratio | 1.12 | ||
| Volatility % | 55.4 | ||
| 14-Day RSI | 82.78 | ||
| 14-Day ATR (₹) | 8.59674 | ||
| 20-Day SMA (₹) | 182.6955 | ||
| 12-1 Month Momentum % | 37.11 | ||
| 52-Week Range (₹) | 87.15 - 216.83 | ||
| Shares Outstanding (Mil) | 86.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ind-Swift Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ind-Swift Laboratories Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ind-Swift Laboratories Ltd Frequently Asked Questions
What is Ind-Swift Laboratories Ltd(NSE:INDSWFTLAB)'s stock price today?
The current price of NSE:INDSWFTLAB is ₹214.16. The 52 week high of NSE:INDSWFTLAB is ₹216.83 and 52 week low is ₹87.15.
When is next earnings date of Ind-Swift Laboratories Ltd(NSE:INDSWFTLAB)?
The next earnings date of Ind-Swift Laboratories Ltd(NSE:INDSWFTLAB) is .
Does Ind-Swift Laboratories Ltd(NSE:INDSWFTLAB) pay dividends? If so, how much?
Ind-Swift Laboratories Ltd(NSE:INDSWFTLAB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Ind-Swift Laboratories Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers